Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
D Blaise, M Attal, J Reiffers, M Michallet, C Bellanger, J L Pico, A M Stoppa, C Payen, G Marit, R Bouabdallah, J J Sotto, J F Rossi, M Brandely, T Hercend, D Maraninchi
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remissionEur Cytokine Netw. 2000 Mar;11(1):91-8.
D Li, W Jiang, J S Bishop, R Ralston, B W O’Malley Jr
Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancerClin Cancer Res. 1999 Jun;5(6):1551-6.
D Maraninchi, N Vey, P Viens, A M Stoppa, E Archimbaud, M Attal, D Baume, R Bouabdallah, F Demeoq, J Fleury, M Michallet, D Olive, J Reiffers, D Sainty, A Tabilio, P Tiberghien, M Brandely, T Hercend, D Blaise
A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemiaLeuk Lymphoma. 1998 Oct;31(3-4):343-9.
Dalil Hannani, Marie Vetizou, David P Enot et al.
Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Cell Research. — 2015. — January 25(3).
David Bray, Shu-Zhen Yu, Hilary Koprowski 2nd, Juong Rhee, Sanjeev Kumar, Federica Pericle, Mohan Suntharalingam, David A Van Echo, Daqing Li, Bert W O’Malley Jr
Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancerArch Otolaryngol Head Neck Surg. 2003 Jun;129(6):618-22.
David F McDermott, Meredith M Regan, Joseph I Clark, Lawrence E Flaherty, Geoffery R Weiss, Theodore F Logan, John M Kirkwood, Michael S Gordon, Jeffrey A Sosman, Marc S Ernstoff, Christopher P G Tretter, Walter J Urba, John W Smith, Kim A Margolin, James
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaJ Clin Oncol. 2005 Jan 1;23(1):133-41.
David L Tamang, Doug Redelman, Bryce N Alves, Leanne Vollger, Christy Bethley, Dorothy Hudig
Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawalCytokine. 2006 Nov;36(3-4):148-59.
David R Snydman 
PDF
Annals of Internal Medicine. — 1990 — 112(2):102-7. DOI:10.7326/0003-4819-112-2-102
David Saadoun, Michelle Rosenzwajg, Florence Joly et al. PDF
New England Journal of Medicine. — 2011. — 365(22):2067-77.
Deborah Charych, Samira Khalili, Vidula Dixit, Peter Kirk, Thomas Chang, John Langowski, Werner Rubas, Stephen K Doberstein, Michael Eldon, Ute Hoch, Jonathan Zalevsky
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyPLoS One. 2017 Jul 5;12(7):e0179431.
Degrate L., Nobili C., Franciosi C. et al.
Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.Langenbecks Arch Surg. 2009 Jan;394(1):115-21. doi: 10.1007/s00423-008-0393-4. Epub 2008 Aug 1.
Degtyareva M.V., Ashitkova N.V., Pankratyeva L.L., Soldatova I.G., Volodin N.N. PDF
Efficacy of human recombinant interleukin-2 (Ronkoleukin®) in treatment of severe neonatal bacterial infections complicated with lymphopenia.
Abstracts of XXII European Congress of Perinatal Medicine. Granada, Spain. 2010. V.23. Supl.1. P.639-640.
Degtyareva M.V., Ashitkova N.V., Pankratyeva L.L., Soldatova I.G., Volodin N.N.
Efficacy of human interleukin-2 (Roncoleukin ) in treatment of severe neonatal bacterial infection complicated with lymphopenia.
The Journal of maternal-fetal & neonatal medicine. 2010. Vol. 23. Suppl. 1. P. 639.
Degtyareva M.V., Soldatova I.G., Pankratyeva L.L. et al. PDF
Clinical efficacy and cost-effectiveness of human recombinant interleukin-2 in neonatal infections.
The Journal of Maternal-Fetal and Neonatal Medicine. June 2012. C.55-56.
Demidov L., Kharkevich G., Tsimafeyev I.
A randomized prospective study of low-dose interleukin-2 (IL-2) in combination with interferon-alpha (IFN) and 5-fluorouracil (5-FU) for metastatic renal cell carcinoma. Final results.
ASCO. 2007. Control/Tracking number: 07-AB-34520-ASCO.
Den Otter W, Maas RA, Koten JW et al.
Effective immunotherapy with local low doses of interleukin-2.In Vivo. 1991 Nov-Dec;5(6):561-5. PMID: 1810439.
Denise Skrombolas, John G Frelinger
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapyExpert Rev Clin Immunol. 2014 Feb;10(2):207-17.
Dihia Meghnem, Sébastien Morisseau, Marie Frutoso, Kilian Trillet, Mike Maillasson, Isabelle Barbieux, Sarah Khaddage, Isabelle Leray, Markus Hildinger, Agnès Quéméner, Yannick Jacques, Erwan Mortier
Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc ReceptorJ Immunol. 2017 Jun 15;198(12):4563-4568.
Dilara Sahin, Onur Boyman PDF
Turk J Immunol 2017; 5(3)61−68.
Djantemirov B.A., Gutov R.A., Karataban S.U., Shishkina T.P.
Application of Roncoleukin® to the treatment of young pyo-septic patients.
Abstacts book of 5th Sci. Meeting of Europ. Soc. of chemotherapy inf. diseases. S.-Petersburg, 1997. P. 57 (R006).
Dominique N Lisiero, Horacio Soto, Linda M Liau, Robert M Prins
Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma modelJ Immunol. 2011 May 1;186(9):5068-77.
Dongyao Wang, Binqing Fu, Xiaokun Shen et al. PDF
Signal Transduction and Targeted Therapy. — 2021.
Douglas J Schwartzentruber, David H Lawson, Jon M Richards et al.
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma.New England Journal of Medicine. — 2011. — June 364(22):2119-27.
Du G, Ye L, Zhang G et al.
Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-γ production.J Cancer Res Clin Oncol. 2012 Oct;138(10):1727-36. doi: 10.1007/s00432-012-1248-5. Epub 2012 Jun 15. PMID: 22699929.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.